Effects of hormonal treatment on lipids in patients with cancer

Filippatos, Theodosios D.; Liberopoulos, Evangelos N.; Pavlidis, N.; Elisaf, Moses; Mikhailidis, DP

doi:10.1016/j.ctrv.2008.09.007

Cited by 48 publications

(36 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Leukemia patients often display dyslipidemia or abnormal plasma/ serum lipid patterns [1][2][3]7,39]. Previous studies have attempted to outline the peculiar features of the lipid profiles in these patients [9].…”

Section: Discussionmentioning

confidence: 99%

Revisiting the dyslipidemia associated with acute leukemia

Usman

Rashid

Ameer

et al. 2015

Clinica Chimica Acta

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Revisiting the dyslipidemia associated with acute leukemia

Usman

Rashid

Ameer

et al. 2015

Clinica Chimica Acta

View full text Add to dashboard Cite

“…In the therapeutic setting it is well known that hormonal treatment exposes patients to possible thrombotic complications and tamoxifen is associated with hyperlipidemia [11,12]. In more recent times, oncologic patients can benefit from multimodality treatment strategies: the concurrent use of cytotoxic polychemotherapy and new molecularly targeted therapy have increased overall response as well as progression-free survival and overall survival time, but the risk of toxicities is also expanded.…”

Section: Introductionmentioning

confidence: 99%

Cancer Chemotherapy and Cardiovascular Risks: Is Capecitabine-Induced Hypertriglyceridemia a Rare Adverse Effect?

Seminara

Losanno²,

Emiliani³

et al. 2010

Cardiology

View full text Add to dashboard Cite

Capecitabine is an oral fluoropyrimidine which is transformed to 5-Fluorouracil inside tumor cells, where it achieves high drug concentrations. Capecitabine is an active drug diffusely utilized in the treatment of various types of tumors, such as breast, colorectal, gastric, head and neck carcinoma. In our experience, capecitabine-induced hypertriglyceridemia does not seem to be a rare adverse effect as it is observed in 10% of treated patients. It is necessary to monitor the lipidic profile of patients treated with capecitabine also in consideration of the frequent presence of comorbidities in cancer populations, the concomitant toxicity related to other drugs used in combination regimens, and cardiovascular effects characteristic of biological target therapy.

show abstract

“…Regarding iatrogenic HTG, the administration of oral estrogens (e.g., for postmenopausal women or as contraceptive pills) may increase the risk of HTG-induced AP [20,21]. Tamoxifen, an antagonist (with some agonist activity) of the estrogen receptor, used for the management of hormone receptor-positive breast cancer, can cause severe HTG, thus increasing the risk of AP [20,22,23].…”

Section: Hypertriglyceridemia-induced Acute Pancreatitis: Clinical Comentioning

confidence: 99%

“…Tamoxifen, an antagonist (with some agonist activity) of the estrogen receptor, used for the management of hormone receptor-positive breast cancer, can cause severe HTG, thus increasing the risk of AP [20,22,23]. Treatment with retinoids for dermato logical disorders also adversely affects TG levels [24].…”

Section: Hypertriglyceridemia-induced Acute Pancreatitis: Clinical Comentioning

confidence: 99%